61 related articles for article (PubMed ID: 16310791)
1. Increased soluble FcgammaRIIIa(Mphi) in plasma from patients with coronary artery diseases.
Masuda M; Miyoshi H; Kobatake S; Nishimura N; Dong XH; Komiyama Y; Takahashi H
Atherosclerosis; 2006 Oct; 188(2):377-83. PubMed ID: 16310791
[TBL] [Abstract][Full Text] [Related]
2. Measurement of soluble Fcgamma receptor type IIIa derived from macrophages in plasma: increase in patients with rheumatoid arthritis.
Masuda M; Morimoto T; Kobatake S; Nishimura N; Nakamoto K; Dong XH; Komiyama Y; Ogawa R; Takahashi H
Clin Exp Immunol; 2003 Jun; 132(3):477-84. PubMed ID: 12780696
[TBL] [Abstract][Full Text] [Related]
3. [Soluble Fc gamma RIIIa derived from macrophages].
Masuda M; Takahashi H
Rinsho Byori; 2003 Nov; 51(11):1102-5. PubMed ID: 14679789
[TBL] [Abstract][Full Text] [Related]
4. Soluble FcgammaRIIIa(Mphi) levels in plasma correlate with carotid maximum intima-media thickness (IMT) in subjects undergoing an annual medical checkup.
Masuda M; Amano K; Hong SY; Nishimura N; Fukui M; Yoshika M; Komiyama Y; Masaki H; Iwasaka T; Takahashi H
Mol Med; 2008; 14(7-8):436-42. PubMed ID: 18475309
[TBL] [Abstract][Full Text] [Related]
5. [Measurement of NK cell and macrophage activation].
Masuda M; Takahashi H
Rinsho Byori; 2011 Jan; 59(1):50-4. PubMed ID: 21404581
[TBL] [Abstract][Full Text] [Related]
6. [Increase of soluble Fc gamma RIIIa derived from macrophages in plasma from patients with atherosclerosis].
Masuda M; Takahashi H
Rinsho Byori; 2002 May; 50(5):502-5. PubMed ID: 12078049
[TBL] [Abstract][Full Text] [Related]
7. Increase of soluble FcgRIIIa derived from natural killer cells and macrophages in plasma from patients with rheumatoid arthritis.
Masuda M; Morimoto T; De Haas M; Nishimura N; Nakamoto K; Okuda K; Komiyama Y; Ogawa R; Takahashi H
J Rheumatol; 2003 Sep; 30(9):1911-7. PubMed ID: 12966590
[TBL] [Abstract][Full Text] [Related]
8. Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease.
Czepluch FS; Kuschicke H; Dellas C; Riggert J; Hasenfuss G; Schäfer K
J Intern Med; 2014 Feb; 275(2):144-54. PubMed ID: 24118494
[TBL] [Abstract][Full Text] [Related]
9. Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease.
Gavasso S; Nygård O; Pedersen ER; Aarseth JH; Bleie O; Myhr KM; Vedeler CA
Atherosclerosis; 2005 Jun; 180(2):277-82. PubMed ID: 15910853
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
11. Human basophils express the glycosylphosphatidylinositol-anchored low-affinity IgG receptor FcgammaRIIIB (CD16B).
Meknache N; Jönsson F; Laurent J; Guinnepain MT; Daëron M
J Immunol; 2009 Feb; 182(4):2542-50. PubMed ID: 19201911
[TBL] [Abstract][Full Text] [Related]
12. Association of cholesteryl ester transfer protein -629C > A polymorphism with high-density lipoprotein cholesterol levels in coronary artery disease patients.
Tanrikulu S; Ademoglu E; Gurdol F; Mutlu-Turkoglu U; Bilge AK; Nisanci Y
Cell Biochem Funct; 2009 Oct; 27(7):452-7. PubMed ID: 19784962
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
14. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
15. The significant increase of FcγRIIIA (CD16), a sensitive marker, in patients with coronary heart disease.
Huang Y; Yin H; Wang J; Ma X; Zhang Y; Chen K
Gene; 2012 Aug; 504(2):284-7. PubMed ID: 22613847
[TBL] [Abstract][Full Text] [Related]
16. [Lipoprotein(a) as a biochemical marker of coronary atherosclerosis].
Ezhov MV; Afanas'ev OI; Benevolenskaia GF; Savchenko AP; Liakishev AA; Pokrovskiĭ SN
Ter Arkh; 1997; 69(9):31-4. PubMed ID: 9411822
[TBL] [Abstract][Full Text] [Related]
17. Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.
Krecki R; Drozdz J; Szcześniak P; Orszulak-Michalak D; Krzemińska-Pakuła M
Kardiol Pol; 2008 Nov; 66(11):1173-80; discussion 1181-2. PubMed ID: 19105094
[TBL] [Abstract][Full Text] [Related]
18. Plasma HDL-cholesterol has an effect on nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary heart disease patients without LDL-hypercholesterolemia.
Tretjakovs P; Kalnins U; Dabina I; Dinne I; Erglis A; Kumsars I; Jurka A
Med Sci Monit; 2000; 6(3):507-11. PubMed ID: 11208362
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease.
Ogasawara K; Mashiba S; Hashimoto H; Kojima S; Matsuno S; Takeya M; Uchida K; Yajima J
Clin Chim Acta; 2008 Nov; 397(1-2):42-7. PubMed ID: 18691566
[TBL] [Abstract][Full Text] [Related]
20. Role of Chlamydia pneumoniae, helicobacter pylori and cytomegalovirus in coronary artery disease.
Al-Ghamdi A; Jiman-Fatani AA; El-Banna H
Pak J Pharm Sci; 2011 Apr; 24(2):95-101. PubMed ID: 21454155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
